---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000012"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T07:04:41.613433+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Recursion Pharma CBO Virani transitions to Senior Strategic Advisor; Kinn joins exec team

## Summary
- Dr. Shafique Virani stepped down as Chief Business Officer effective Feb 6, 2024, to become Senior Strategic Advisor.
- Matthew Kinn, previously SVP Business Development, assumes all CBO responsibilities on Recursion's executive team.
- Virani receives advisory fees of $1,000/hour (min $25k/month Feb–Jul, then $15k/month) and continued equity vesting.
- If terminated before Aug 1, 2024, Virani gets a lump sum starting at $390k (Feb) decreasing $65k/month.

## SEC filing metadata
- accession: 0001601830-24-000012
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000012/0001601830-24-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000012/rxrx-20240206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000012
- JSON: https://secwatch.observer/filing/0001601830-24-000012.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000012.txt

## Key facts
- Executive change
  Shafique Virani changed role as Senior Strategic Advisor at RECURSION PHARMACEUTICALS, INC..
  - Action: transitioned
  - Role: Senior Strategic Advisor
  source text: Dr. Shafique Virani, the Chief Business Officer of Recursion Pharmaceuticals, Inc. (the “Company” or “Recursion”) transitioned into a new role as a Senior Strategic Advisor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000012/0001601830-24-000012-index.htm
- Executive change
  Matthew Kinn was appointed as Chief Business Officer at RECURSION PHARMACEUTICALS, INC..
  - Action: joined
  - Role: Chief Business Officer
  source text: Matthew Kinn, Senior Vice President, Business Development and Corporate Initiatives joined Recursion’s executive team and assumed all responsibilities previously held by Dr. Virani.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000012/0001601830-24-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.